Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aldeyra Therapeutics, Inc. (ALDX)Business Wire • 08/10/23
Aldeyra Therapeutics, Inc. (ALDX) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Aldeyra Therapeutics, Inc. Securities Class ActionBusiness Wire • 08/08/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) InvestorsBusiness Wire • 08/08/23
ALDEYRA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the FirmBusiness Wire • 08/08/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aldeyra Therapeutics, Inc. (ALDX) InvestorsBusiness Wire • 08/07/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Aldeyra Therapeutics, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 08/06/23
ALDX INVESTOR NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALDXPRNewsWire • 08/03/23
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of InvestorsBusiness Wire • 08/03/23
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of InvestorsBusiness Wire • 08/03/23
The Law Offices of Frank R. Cruz Announces Investigation of Aldeyra Therapeutics, Inc. (ALDX) on Behalf of InvestorsBusiness Wire • 08/03/23
EQUITY ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALDXBusiness Wire • 08/02/23
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Aldeyra Therapeutics, Inc. (ALDX)Business Wire • 08/01/23
Can Aldeyra Therapeutics, Inc. (ALDX) Climb 107.66% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 07/20/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDXPRNewsWire • 07/17/23
Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With ReproxalapSeeking Alpha • 07/10/23
Aldeyra Therapeutics Announces Improvement from Baseline in Retinal Function in Phase 2 Clinical Trial of ADX‑2191 in Patients with Retinitis PigmentosaBusiness Wire • 06/29/23
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX-2191 in Patients with Retinitis PigmentosaBusiness Wire • 06/28/23
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX‑629 in Patients With Chronic CoughBusiness Wire • 06/27/23
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 2 Clinical Trial of ADX‑629 in Patients with Chronic CoughBusiness Wire • 06/26/23
Aldeyra's Stellar Allergic Conjunctivitis Results To Raise Reproxalap Monetization ValueSeeking Alpha • 06/16/23
